I love the difference in styles between SR and DW.
SR is talking to everyone with industry ears attentive, yet commercial at the same time.
DW is an entrepreneur, goes to the root of the issue for teh company and shareholders with a growth / commercial overtone.
For example the announcement is formal and specifically related to Trials related to Diabetic Foot Ulcers, but DW goes further to mention venous leg ulcers. (as the product is designed for both). DW just gets you thinking of the commercial opportunities right out front. Got to love them both, I think this is going to be a beautiful combination.
GLTAH
Ann: First Patient enrolled - SynPath Diabetic Foot Ulcer Trial, page-12
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.38 |
Change
-0.030(1.24%) |
Mkt cap ! $1.642B | |||
| Open | High | Low | Value | Volume |
| $2.42 | $2.44 | $2.36 | $4.288M | 1.798M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 28177 | $2.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.38 | 26895 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |